303 related articles for article (PubMed ID: 31539267)
1. Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer.
Siah KW; Khozin S; Wong CH; Lo AW
JCO Clin Cancer Inform; 2019 Sep; 3():1-11. PubMed ID: 31539267
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
5. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Thorac Cancer; 2019 Dec; 10(12):2259-2266. PubMed ID: 31679185
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
7. Impact of Targeted Therapy on the Survival of Patients With Advanced-Stage Non-small Cell Lung Cancer in Oncosalud - AUNA.
Aguilar A; Mas L; Enríquez D; Vallejos C; Gutarra R; Flores CJ
Cancer Control; 2022; 29():10732748211068637. PubMed ID: 35030060
[TBL] [Abstract][Full Text] [Related]
8. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
11. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
[TBL] [Abstract][Full Text] [Related]
12. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
13. Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis.
Sun W; Jiang M; Dang J; Chang P; Yin FF
Radiat Oncol; 2018 Oct; 13(1):197. PubMed ID: 30290849
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
[TBL] [Abstract][Full Text] [Related]
15. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
[TBL] [Abstract][Full Text] [Related]
16. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
17. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
18. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
[TBL] [Abstract][Full Text] [Related]
19. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis.
Zhou F; Jiang T; Ma W; Gao G; Chen X; Zhou C
Lung Cancer; 2015 Aug; 89(2):203-11. PubMed ID: 26115839
[TBL] [Abstract][Full Text] [Related]
20. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
Chen B; Zhao G; Ma Q; Ji B; Ji T; Xin H; Gao S
Int J Clin Exp Pathol; 2015; 8(12):16064-72. PubMed ID: 26884883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]